Document is current
Any future updates will be listed below
-
Authors
Shaked, Abraham https://orcid.org/0000-0002-2162-095X
Sagar, Alex
Olthoff, Kim M.
Abt, Peter L.
Vail, Emily A. https://orcid.org/0000-0002-1849-5780
Martin, Niels D. https://orcid.org/0000-0002-2157-0825
Abrams, Charles S.
Hasz, Rick D.
Radolovic, Christine
Kaminski, Shannon
Loza, Bao-Li https://orcid.org/0000-0003-3917-6129
Markmann, James F. https://orcid.org/0000-0002-2762-6535
Low, Susan C.
Curtis, Mike
Lanieri, Leanne
Swenson, Kirsten G.
Everson, Gregory T.
Wagner, David A.
Elzawahry, Mohamed A. https://orcid.org/0000-0001-5300-912X
Fallon, John I. https://orcid.org/0000-0002-8644-9380
Abbas, Syed Hussain
Fortuna, Danielle
Furth, Emma E.
Reddy, K. Rajender https://orcid.org/0000-0002-4898-7778
Reese, Peter P.
Friend, Peter https://orcid.org/0000-0003-0841-9685
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 19 December 2025
First Online: 9 February 2026
Competing interests
: Unrelated to the present work, A. Shaked is supported by grants from the National Institutes of Health (NIH) to the University of Pennsylvania. Unrelated to the present work, E.A.V. is supported by grants from the NIH and the Transplant Foundation to the University of Pennsylvania. Unrelated to the present work, C.S.A. received honoraria from UpToDate. Unrelated to the present work, P.P.R. has received support from grants from the NIH, Merck, Gilead, Moderna and eGenesis to the University of Pennsylvania; he also receives payments from Elsevier for his work as Associate Editor of the American Journal of Kidney Diseases . Unrelated to the present work, P.L.A. discloses funding from the Transplant Foundation. Unrelated to the present work, N.D.M. discloses consulting with AstraZeneca, Nestle and FloBio and is a governing board member at the Gift of Life Donor Program. J.F.M. discloses serving on the Scientific Advisory Board for eGenesis and iTolerance and the Clinical Advisory Board for Transmedics. G.T.E. is an employee and equity member of HepQuant. D.A.W. is President at Metabolic Solutions. P.F. is a cofounder, stockholder and Chief Medical Officer of OrganOx. He is named as an inventor on the patent that supports the underlying perfusion technology of the metra. S.C.L., M.C., L.L. and K.G.S. are employees of eGenesis. A. Sagar, J.I.F., M.A.E. and S.H.A. have received consulting fees from OrganOx. S.H.A. has received academic clinical lectureship funding from Santersus. Unrelated to the present work, K.R.R. has received support from Mallinckrodt, Exact Sciences, Bristol Myers Squibb, Intercept, Merck, Gilead, Grifols, Sequana, HCC-TARGET, NASHÂ TARGET, BioVie, Regeneron, Camarus, GSK and Band D Instruments; royalties from UpToDate; consulting fees from Spark Therapeutics, Mallinckrodt, Novo Nordisk, Pfizer, BioVie and Genfit; served on the Data and Safety Monitoring Boards for Novartis, AstraZeneca, Genkyotex and Arbutus; and has received compensation from Gastroenterology for his work as Associate Editor and uncompensated as Co-Chair on the AASLD Task Force for COVID-19. The other authors declare no competing interests.
